Developer docs
API playgroundTry for free, no card

Search company profiles

Kano Therapeutics

Full company profile

uuid00021fd

Namestring
Kano Therapeutics
Legal namestring
Kano Therapeutics
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Kano Therapeutics is an MIT spinout founded in 2021 that develops circular single-stranded DNA (cssDNA) templates, marketed as KanoDNA, for use as genetic payloads in cell and gene therapy applications. The company's core technology addresses what it characterizes as a fundamental industry bottleneck: the lack of high-quality, scalable DNA donor templates for precise gene editing. KanoDNA is engineered at the topology and 3D-feature level to influence stability, intracellular behavior, and downstream performance, with the company reporting 3-5X more edited cells compared to alternative DNA templates in homology-directed repair workflows using CRISPR nucleases. The platform is indication-, disease-, and technology-agnostic and is positioned for use in CAR-T and gene correction therapies, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Manufacturing uses industrial fermentation analogous to biologics and plasmid DNA production rather than traditional chemical or enzymatic methods, which the company argues resolves the economic scalability barrier of conventional ssDNA production.

The company's go-to-market is enterprise B2B, licensing DNA products and supplying them through integrated partnerships with biotechnology and pharmaceutical companies. Kano's commercial motion starts with low-friction evaluation agreements that let partners generate data in their own systems, then progresses to full partnerships with integrated DNA supply spanning discovery through GMP. The integrated platform combines three core functional units: design, manufacturing, and screening, marketed as a one-stop solution. Kano serves two primary customer segments: cell and gene therapy developers and gene editing technology companies. Pricing is not publicly disclosed; the model aligns with licensing/royalty and supply agreements typical of platform reagent and CDMO-style biotechs. No customer logos or revenue figures are disclosed, and the company is pre-commercial at the seed stage.

Kano was co-founded by Dr. Floris Engelhardt (CEO/CSO), a physicist with a PhD from the Technical University of Munich who completed her postdoctoral work in Mark Bathe's BatheBioNano lab at MIT, and John Vroom (CBO), an MIT Sloan MBA with prior life sciences consulting experience across 50+ engagements. The company is headquartered at 238 Main Street, Cambridge, MA 02142, and operates with a team of approximately 10-15 including founders, Director CMC, Lead Platform Engineering, Lead Preclinical Biology, a Senior Research Associate, and an undergraduate co-op. Disclosed total funding is $7.1 million, anchored by an oversubscribed $5 million seed round in August 2024 co-led by The Engine Ventures and VSquared Ventures with Taihill Venture and Metaplanet participating, plus a $2.1M round in 2022. 2025 strategic actions include a collaboration with Merck KGaA announced September 4, acceptance into the NVIDIA Inception program on September 3, and receipt of a Massachusetts Manufacturing Innovation Initiative (M2I2) grant on October 29. Seth Ettenberg was appointed as an independent board director with BlueRock Therapeutics lineage.

Short descriptiontext

Kano Therapeutics is an MIT spinout that develops circular single-stranded DNA templates branded as KanoDNA, licensing them as scalable genetic payloads for cell and gene therapy developers and gene editing companies via integrated partnerships from discovery through GMP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
circular single-stranded DNA, gene editing templates, cell and gene therapy, DNA payload manufacturing, non-viral gene insertion
Industry3 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell and Gene Therapy DNA Templates
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1DNA Product Licensing and Supply
TypeLicensing Royalties
Description

License DNA products and supply them through integrated partnerships. Partners access evaluation agreements, then full partnerships with integrated DNA supply from discovery through GMP.

kanotherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kano Therapeutics develops and manufactures KanoDNA, a circular single-stranded DNA (cssDNA) template used as a gene-editing payload for cell and gene therapy developers. The company licenses its cssDNA products and supplies them through integrated partnerships spanning discovery, process development, and GMP manufacturing. Production relies on a proprietary fermentation-based process rather than traditional chemical or enzymatic synthesis, enabling scalable, GMP-ready supply of high-fidelity, immune-quiet DNA templates for applications such as HDR with CRISPR, recombinase/transposon insertion, and episomal expression.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 3-5X more edited cells than other DNA templates in HDR with CRISPR nucleases
Product overview1 text field

Kano Therapeutics operates as a single unified platform built around its KanoDNA circular single-stranded DNA (cssDNA) product, which connects three core functional units: design, manufacturing, and screening. The platform offers DNA products and integrated partnership services, enabling partners to license DNA products and access full support from discovery through GMP supply. KanoDNA functions as the missing payload layer in cell and gene therapy, supporting applications including HDR with CRISPR nucleases for CAR-T and gene correction therapies, targeted insertion with next-generation editing tools, and non-integrating DNA templates for episomal expression. The platform is indication-, disease-, and technology-agnostic, designed to enable the broadest therapeutic impact across genetic medicine.

Product and service1 record
1KanoDNA (circular single-stranded DNA / cssDNA)
CategoryGene editing DNA templates / cell and gene therapy inputs
Description

Circular single-stranded DNA templates designed for high-fidelity gene editing, immune-quiet delivery, and scalable manufacturing via fermentation-based production. Used by cell and gene therapy developers for HDR with CRISPR nucleases, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Offered through integrated licensing and supply partnerships from discovery through GMP.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Merck KGaA, Darmstadt, Germany
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

Collaboration announced in September 2025. Nature of collaboration focused on DNA templates and genetic medicine development.

kanotherapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IDT is a leading global supplier of custom oligonucleotides and nucleic acid reagents, including ssDNA and dsDNA donors used in gene editing. It is the closest incumbent comparable in supplying research-through-GMP DNA for cell and gene therapy developers, though it does not specialize in circular ssDNA.

TypeDirect peer
Description

Twist provides synthetic DNA and gene fragments at scale using a silicon-based DNA writing platform, serving antibody discovery, synthetic biology, and gene therapy applications. It competes directly with Kano in providing engineered DNA payloads for next-generation therapeutics.

TypeBroad incumbent
Description

GenScript offers gene synthesis, plasmid manufacturing, and cell therapy services including DNA and protein reagents for gene editing. It is a comparable incumbent supplying DNA templates and related services to the cell and gene therapy ecosystem.

TypeDirect peer
Description

Aldevron (now part of Danaher) manufactures plasmid DNA, mRNA, and proteins used in gene and cell therapies, including as donor templates. It is a direct comparable in GMP-grade nucleic acid manufacturing for cell and gene therapy developers.

TypeEmerging player
Description

Codex DNA (formerly Synthetic Genomics) develops automated DNA synthesis and assembly platforms for synthetic biology and therapeutic applications. It overlaps with Kano in providing synthetic DNA building blocks for advanced therapeutics.

TypeEmerging player
Description

Ansa is developing enzymatic DNA synthesis technology to produce long, high-fidelity oligonucleotides and gene fragments. It is an emerging competitor targeting the same DNA payload / template need for gene therapy and synthetic biology.

7DNA Script
TypeEmerging player
Description

DNA Script builds enzymatic DNA synthesis platforms (Syntax platform) for producing oligonucleotides on demand. It is comparable to Kano as an alternative next-generation DNA synthesis approach serving research and therapeutic customers.

TypeDirect peer
Description

Synthego supplies synthetic guide RNAs and gene editing tools, including engineered DNA/RNA reagents for cell and gene therapy developers. It is directly comparable as a developer of nucleic acid payloads serving the same gene editing customer base.

TypeDirect peer
Description

TriLink (part of Maravai LifeSciences) manufactures mRNA, plasmid DNA, and nucleic acid reagents for therapeutic and vaccine applications. It is a direct peer as a GMP-grade nucleic acid supplier to cell and gene therapy developers.

TypeBroad incumbent
Description

Eurofins Genomics offers DNA synthesis, gene synthesis, and oligonucleotide manufacturing services globally. It is a broader incumbent supplying custom DNA to research and therapeutic customers, with overlap in the gene therapy DNA template market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kano Therapeutics

Cell and Gene Therapy DNA Templateskanotherapeutics.com

Kano Therapeutics is an MIT spinout that develops circular single-stranded DNA templates branded as KanoDNA, licensing them as scalable genetic payloads for cell and gene therapy developers and gene editing companies via integrated partnerships from discovery through GMP.

What Kano Therapeutics does

Kano Therapeutics is an MIT spinout founded in 2021 that develops circular single-stranded DNA (cssDNA) templates, marketed as KanoDNA, for use as genetic payloads in cell and gene therapy applications. The company's core technology addresses what it characterizes as a fundamental industry bottleneck: the lack of high-quality, scalable DNA donor templates for precise gene editing. KanoDNA is engineered at the topology and 3D-feature level to influence stability, intracellular behavior, and downstream performance, with the company reporting 3-5X more edited cells compared to alternative DNA templates in homology-directed repair workflows using CRISPR nucleases. The platform is indication-, disease-, and technology-agnostic and is positioned for use in CAR-T and gene correction therapies, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Manufacturing uses industrial fermentation analogous to biologics and plasmid DNA production rather than traditional chemical or enzymatic methods, which the company argues resolves the economic scalability barrier of conventional ssDNA production.

The company's go-to-market is enterprise B2B, licensing DNA products and supplying them through integrated partnerships with biotechnology and pharmaceutical companies. Kano's commercial motion starts with low-friction evaluation agreements that let partners generate data in their own systems, then progresses to full partnerships with integrated DNA supply spanning discovery through GMP. The integrated platform combines three core functional units: design, manufacturing, and screening, marketed as a one-stop solution. Kano serves two primary customer segments: cell and gene therapy developers and gene editing technology companies. Pricing is not publicly disclosed; the model aligns with licensing/royalty and supply agreements typical of platform reagent and CDMO-style biotechs. No customer logos or revenue figures are disclosed, and the company is pre-commercial at the seed stage.

Kano was co-founded by Dr. Floris Engelhardt (CEO/CSO), a physicist with a PhD from the Technical University of Munich who completed her postdoctoral work in Mark Bathe's BatheBioNano lab at MIT, and John Vroom (CBO), an MIT Sloan MBA with prior life sciences consulting experience across 50+ engagements. The company is headquartered at 238 Main Street, Cambridge, MA 02142, and operates with a team of approximately 10-15 including founders, Director CMC, Lead Platform Engineering, Lead Preclinical Biology, a Senior Research Associate, and an undergraduate co-op. Disclosed total funding is $7.1 million, anchored by an oversubscribed $5 million seed round in August 2024 co-led by The Engine Ventures and VSquared Ventures with Taihill Venture and Metaplanet participating, plus a $2.1M round in 2022. 2025 strategic actions include a collaboration with Merck KGaA announced September 4, acceptance into the NVIDIA Inception program on September 3, and receipt of a Massachusetts Manufacturing Innovation Initiative (M2I2) grant on October 29. Seth Ettenberg was appointed as an independent board director with BlueRock Therapeutics lineage.

Kano Therapeutics firmographics

Firmographics
Name
Kano Therapeutics
Legal name
Kano Therapeutics
Website
https://kanotherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Kano Therapeutics is an MIT spinout that develops circular single-stranded DNA templates branded as KanoDNA, licensing them as scalable genetic payloads for cell and gene therapy developers and gene editing companies via integrated partnerships from discovery through GMP.
Ownership category
akta.pro rank

Kano Therapeutics industry classification

Industry
Product category
Cell and Gene Therapy DNA Templates
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Circular single-stranded DNA
  • Gene editing templates
  • Cell and gene therapy
  • DNA payload manufacturing
  • Non-viral gene insertion

Where Kano Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kano Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. DNA Product Licensing and Supply: License DNA products and supply them through integrated partnerships. Partners access evaluation agreements, then full partnerships with integrated DNA supply from discovery through GMP.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Kano Therapeutics product offering

Product offering

Core offering

Kano Therapeutics develops and manufactures KanoDNA, a circular single-stranded DNA (cssDNA) template used as a gene-editing payload for cell and gene therapy developers. The company licenses its cssDNA products and supplies them through integrated partnerships spanning discovery, process development, and GMP manufacturing. Production relies on a proprietary fermentation-based process rather than traditional chemical or enzymatic synthesis, enabling scalable, GMP-ready supply of high-fidelity, immune-quiet DNA templates for applications such as HDR with CRISPR, recombinase/transposon insertion, and episomal expression.

Product overview

Kano Therapeutics operates as a single unified platform built around its KanoDNA circular single-stranded DNA (cssDNA) product, which connects three core functional units: design, manufacturing, and screening. The platform offers DNA products and integrated partnership services, enabling partners to license DNA products and access full support from discovery through GMP supply. KanoDNA functions as the missing payload layer in cell and gene therapy, supporting applications including HDR with CRISPR nucleases for CAR-T and gene correction therapies, targeted insertion with next-generation editing tools, and non-integrating DNA templates for episomal expression. The platform is indication-, disease-, and technology-agnostic, designed to enable the broadest therapeutic impact across genetic medicine.

Differentiator

Problem solved

Functional benefit

Products and services

  • KanoDNA (circular single-stranded DNA / cssDNA) Circular single-stranded DNA templates designed for high-fidelity gene editing, immune-quiet delivery, and scalable manufacturing via fermentation-based production. Used by cell and gene therapy developers for HDR with CRISPR nucleases, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression of programmable genetic constructs. Offered through integrated licensing and supply partnerships from discovery through GMP.

Quantifiable outcome

  • 3-5X more edited cells than other DNA templates in HDR with CRISPR nucleases

Companies that use Kano Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Kano Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kano Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 4 September 2025Collaboration announced in September 2025. Nature of collaboration focused on DNA templates and genetic medicine development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Kano Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Integrated DNA Technologies (IDT): IDT is a leading global supplier of custom oligonucleotides and nucleic acid reagents, including ssDNA and dsDNA donors used in gene editing. It is the closest incumbent comparable in supplying research-through-GMP DNA for cell and gene therapy developers, though it does not specialize in circular ssDNA.
  • GenScript: GenScript offers gene synthesis, plasmid manufacturing, and cell therapy services including DNA and protein reagents for gene editing. It is a comparable incumbent supplying DNA templates and related services to the cell and gene therapy ecosystem.
  • Eurofins Genomics: Eurofins Genomics offers DNA synthesis, gene synthesis, and oligonucleotide manufacturing services globally. It is a broader incumbent supplying custom DNA to research and therapeutic customers, with overlap in the gene therapy DNA template market.

Direct peers

  • Twist Bioscience: Twist provides synthetic DNA and gene fragments at scale using a silicon-based DNA writing platform, serving antibody discovery, synthetic biology, and gene therapy applications. It competes directly with Kano in providing engineered DNA payloads for next-generation therapeutics.
  • Aldevron: Aldevron (now part of Danaher) manufactures plasmid DNA, mRNA, and proteins used in gene and cell therapies, including as donor templates. It is a direct comparable in GMP-grade nucleic acid manufacturing for cell and gene therapy developers.
  • Synthego: Synthego supplies synthetic guide RNAs and gene editing tools, including engineered DNA/RNA reagents for cell and gene therapy developers. It is directly comparable as a developer of nucleic acid payloads serving the same gene editing customer base.
  • TriLink BioTechnologies: TriLink (part of Maravai LifeSciences) manufactures mRNA, plasmid DNA, and nucleic acid reagents for therapeutic and vaccine applications. It is a direct peer as a GMP-grade nucleic acid supplier to cell and gene therapy developers.

Emerging players

  • Codex DNA: Codex DNA (formerly Synthetic Genomics) develops automated DNA synthesis and assembly platforms for synthetic biology and therapeutic applications. It overlaps with Kano in providing synthetic DNA building blocks for advanced therapeutics.
  • Ansa Biotechnologies: Ansa is developing enzymatic DNA synthesis technology to produce long, high-fidelity oligonucleotides and gene fragments. It is an emerging competitor targeting the same DNA payload / template need for gene therapy and synthetic biology.
  • DNA Script: DNA Script builds enzymatic DNA synthesis platforms (Syntax platform) for producing oligonucleotides on demand. It is comparable to Kano as an alternative next-generation DNA synthesis approach serving research and therapeutic customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kano Therapeutics social profiles

Digital presence

Kano Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kano Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Kano Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kano Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kano Therapeutics

What does Kano Therapeutics do?

Kano Therapeutics develops and manufactures KanoDNA, a circular single-stranded DNA (cssDNA) template used as a gene-editing payload for cell and gene therapy developers. The company licenses its cssDNA products and supplies them through integrated partnerships spanning discovery, process development, and GMP manufacturing. Production relies on a proprietary fermentation-based process rather than traditional chemical or enzymatic synthesis, enabling scalable, GMP-ready supply of high-fidelity, immune-quiet DNA templates for applications such as HDR with CRISPR, recombinase/transposon insertion, and episomal expression.

Is Kano Therapeutics a public or private company?

Kano Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kano Therapeutics founded?

Kano Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Kano Therapeutics based?

Kano Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Kano Therapeutics make money?

One revenue line is on record: DNA Product Licensing and Supply.

Who are Kano Therapeutics's main competitors?

Broad incumbents on record are Integrated DNA Technologies (IDT), GenScript and Eurofins Genomics. Direct peers are Twist Bioscience, Aldevron, Synthego and TriLink BioTechnologies. Emerging players are Codex DNA, Ansa Biotechnologies and DNA Script.

Does Kano Therapeutics have an API?

No public API is recorded for Kano Therapeutics.

What industry is Kano Therapeutics in?

Kano Therapeutics's product category is Cell and Gene Therapy DNA Templates. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MITA better DNA material for genetic medicineKano Therapeutics, a biotech company founded by former MIT researchers, is developing a gene-editing platform using circular single-stranded DNA (cssDNA), which the company says is less toxic than traditional double-stranded DNA and more stable than RNA for delivering genetic material. The company has formed a collaboration with Merck KGaA combining its cssDNA platform with the pharmaceutical giant's lipid nanoparticle delivery solutions for gene therapies. Kano won the $20,000 first place prize at the MIT Sloan Healthcare Innovation Prize in 2021 and is seeking partnerships with additional pharmaceutical companies to bring cancer drugs into clinical development over the next two years.American City Business JournalsThe Petri Dish: Kano Therapeutics; Tevard moves to Lilly Gateway Labs; AscidianKano Therapeutics raised $5 million in seed funding, bringing total funding to $7.1 million. Ascidian Therapeutics promoted a chief scientific officer and named a chief people officer, with a Roche partnership offering up to $1.8 billion in milestone payments. Tevard Biosciences moved its headquarters to Lilly Gateway Labs, retaining ownership of its assets.Pulse 2.0Kano Therapeutics: $7.1 Million Raised To Create ssDNA As Flexible Biomolecule For Gene InsertionsKano Therapeutics has secured an oversubscribed $5 million seed round, bringing its total funding to $7.1 million, led by The Engine Ventures and VSquared Ventures. The capital will be used to develop GLP standards, design clinical-grade production processes for kilobase ssDNA, and advance collaborative drug development programs. This funding supports the company's mission to provide a safer, more efficient biomolecule platform for gene insertions in genetic therapies.VC News DailyKano Therapeutics Secures $7.1MKano Therapeutics secured an oversubscribed $5 million seed round for its biotechnology development. The funding was co-led by Engine Ventures and VSquared Ventures, with participation from Taihill Venture and Metaplanet.Venture Capital Access OnlineKano Therapeutics Secures $7.1M to Bring Targeted, Non-Viral DNA Insertion Technology to Genetic MedicineKano Therapeutics secured an oversubscribed $5 million seed funding round, bringing its total capital to $7.1 million to advance its single-stranded DNA (ssDNA) gene insertion technology. The investment, led by The Engine Ventures and VSquared Ventures, will support the development of GLP standards and clinical-grade production processes for the company's bioreactor-based manufacturing platform. This funding aims to scale the production of ssDNA at lower costs to facilitate targeted, non-viral gene therapies for complex genetic diseases.FinSMEsKano Therapeutics Raises $5M in Seed FundingKano Therapeutics raised $5 million in seed funding, bringing its total capitalization to $7.1 million, with investment led by The Engine Ventures and VSquared Ventures. The company plans to utilize these funds to establish good laboratory practice standards and advance the clinical-grade production of kilobase single-stranded DNA for gene therapies.MITMIT team improving gene therapies wins Sloan health care prizeMIT team Kano Therapeutics won the 2021 Sloan Healthcare Innovations Prize for its novel single-stranded DNA production method. The technology aims to make gene therapies safer, more personalized, and cheaper, with the team earning $20,000. The prize was one of eight finalists at the MIT Sloan competition.